NCT01090011 - Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

171

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

August 31, 2014

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Cetuximab

BIBW 2992 medium dose plus high dose level of cetuximab

DRUG

Cetuximab

BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added

DRUG

BIBW 2992

BIBW 2992 medium dose plus high dose level of cetuximab

DRUG

BIBW 2992

BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added

Trial Locations (6)

1200.71.1004 Boehringer Ingelheim Investigational Site, Aurora

1200.71.1003 Boehringer Ingelheim Investigational Site, New Haven

1200.71.1001 Boehringer Ingelheim Investigational Site, New York

1200.71.1002 Boehringer Ingelheim Investigational Site, Nashville

1200.71.2002 Boehringer Ingelheim Investigational Site, Amsterdam

1200.71.2001 Boehringer Ingelheim Investigational Site, Groningen